N-Benzyl-N-ethyl-benzenesulfonamide | 74805-37-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Benzyl-N-ethyl-benzenesulfonamide
• 英文别名: N-benzyl-N-ethylbenzenesulfonamide
• CAS: 74805-37-1
• 化学式: C₁₅H₁₇NO₂S
• mdl: MFCD01212632
• 分子量: 275.371
• InChiKey: IVRVDQCUNWLFDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-Benzyl-N-ethyl-benzenesulfonamide 在 Oxone 、 potassium bromide 作用下， 以 硝基甲烷 为溶剂， 反应 24.0h， 以87%的产率得到N-乙基苯磺酰胺
  参考文献：
  名称：

  Oxidative Debenzylation of N-Benzyl Amides and O-Benzyl Ethers Using Alkali Metal Bromide

  摘要：

  The oxidative debenzylation of N-benzyl amides and O-benzyl ethers was promoted with high efficiency by a bromo radical formed through the oxidation of bromide from alkali metal bromide under mild conditions. This reaction provided the corresponding amides from N-benzyl amides and carbonyl compounds from O-benzyl ethers in high yields.

  DOI：

  10.1021/ol501703y
• 作为产物：
  描述：

  1-Benzyl-2,4,6-triphenylpyridinium tetrafluoroborate 、 sodium N-ethylbenzenesulphonamide 在 2,4,6-三苯基吡啶 作用下， 以48%的产率得到N-Benzyl-N-ethyl-benzenesulfonamide
  参考文献：
  名称：

  Katritzky, Alan R.; Liso, Gaietano; Lunt, Edward, Journal of the Chemical Society. Perkin transactions I, 1980, p. 849 - 851

  摘要：

  DOI：

文献信息

• Triazolopyridine inhibitors of myeloperoxidase and/or EPX
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11008317B2

  公开（公告）日：2021-05-18

  The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

  本发明提供了式(I)化合物；其中各取代基如说明书中所定义，以及包含任何此类新型化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用于治疗和/或预防动脉粥样硬化、心力衰竭、慢性阻塞性肺病（COPD）及相关疾病。
• KATRITZKY A. R.; LISO G.; LUNT E.; PATEL R. C.; THIND S. S.; ZIA A., J. CHEM. SOC. PERKIN TRANS., PART 1, 1980, NO 4, 849-851
  作者：KATRITZKY A. R.、 LISO G.、 LUNT E.、 PATEL R. C.、 THIND S. S.、 ZIA A.

  DOI：——

  日期：——
• 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
  申请人：Merck & Co., Inc.

  公开号：EP2097385A1

  公开（公告）日：2009-09-09
• TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX
  申请人：Bristol-Myers Squibb Company

  公开号：US20200291016A1

  公开（公告）日：2020-09-17

  The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
• [EN] 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS<br/>[FR] DÉRIVES DE 2-[1-PHÉNYL-5-HYDROXY OU METHOXY-4ALPHA-MÉTHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ÉTHYLE PHÉNYLE UTILISES COMME LIGANDS DE RÉCEPTEUR DE GLUCOCORTICOIDE
  申请人：MERCK & CO INC

  公开号：WO2008051532A1

  公开（公告）日：2008-05-02

  [EN] The present invention is directed to 2- [l-phenyl-5 -hydroxy or methoxy-4alpha- methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives of formula I (I) as glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
  [FR] L'invention concerne des derivés de 2- [l-phényl-5 -hydroxy ou méthoxy-4alpha- méthyl-hexahydrocyclopenta[f]indazol-5-yl]éthyle phényle correspondant à la formule (I) utilisés comme ligands de récepteur de glucocorticoïde utiles dans le traitement de diverses maladies ou états auto-immunes ou inflammatoires. L'invention concerne également des compositions pharmaceutiques et des procédés d'utilisation.